~~<i id='302BDDD36F'><strike id='302BDDD36F'><tt id='302BDDD36F'><pre id='302BDDD36F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：knowledge 2025-10-01 04:45:02 - browse：9384

Monica Bertagnolli -- health policy coverage from STAT — NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

“It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： CDC director unscathed in first congressional testimony

focus

explore

Whatcausesourearstopopandwhataretheydoing,exactly?AlexHogan,MatthewOrr/STATTakingoffinanairplanealwa

WSS

Medicare Advantage enrollment hits roughly 33.4 million

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

As biotech industry slumps, bioscience job market is upside down

In 'major milestone,' FDA approves first cell therapy for solid tumors

Cigna, Humana reportedly in talks to merge

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

hotspot

entertainment

focus

Wildfire smoke exposes gaps in outdoor worker protections

With clinical trial data readouts, here's how to spot spin

How one medical school became remarkably diverse

Obamacare plans could cover weight loss drugs

Apple is now the first public company to be valued at $3 trillion

Pediatric cancer treatments threatened by a new FDA policy

Psychedelics group wrestles with new pharma identity

New study raises questions about niacin and heart health

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ReNAgade cuts staff seven months after raising $300 million

focus

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Opioid cravings were reduced by anti

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

The EPA's new lead rule: How one expert crunched the numbers

FDA investigates CAR

Secretariat’s lessons for human medicine

focus

focus

focus

explore